What signs indicate potential fat emboli in the patient with a fractured left femur?
A) Increased partial pressure of arterial oxygen (PaO2), reduced sensation in left leg or foot
B) Left leg pain, dyspnea
C) Bradycardia, skin bruises
D) Cyanosis, decreased PaO2
Ans: D
Feedback: Fat emboli may occur with fractures of the long bones and pelvis and may be fatal. Clinical manifestations include cyanosis, dyspnea, tachycardia, chest pain, tachypnea, apprehension, restlessness, confusion, petechiae, and decreased PaO2. Increased PaO2, reduced sensation in the left leg or foot, pain in the affected extremity, skin bruises, and bradycardia aren't associated with fat emboli.
You might also like to view...
The nurse notes that a client who is in renal failure is taking a drug that is excreted by the kidneys. The nurse is concerned about administering this drug because:
1. the drug might not work on the client. 2. the drug could accumulate to toxic levels in the blood. 3. the drug will be excreted in the stool. 4. the drug will be excreted by the liver.
A patient with a water-sealed chest tube unit is connected to suction. Patient care is correct if the nurse takes which action?
a. Monitors the bubbling of sterile water in the water-seal chamber b. Strips the tube every 2 hours for 15 seconds to prevent clots c. Clamps the chest tube when transporting the patient d. Keeps two toothed clamps at the bedside for an emergency
Jeffrey has atopic dermatitis. You are prescribing a low-dose topical corticosteroid for him. Which would be a good choice?
a. Betamethasone dipropionate 0.05% c. Halcinonide 0.1% b. Hydrocortisone base 2.5% d. Desonide 0.05%
The nurse is caring for an elderly patient who is status-post right hip open-reduction internal fixation (ORIF)
The patient is taking oxycodone (OxyContin) every 6 hours as needed for pain and chlorpheniramine (Chlor-Trimeton) daily. The nurse discusses obtaining an order from the prescriber for which of the following medications? a. GoLYTELY b. Lactulose c. Docusate sodium (Colace) d. Polyethylene glycol (MiraLax)